MEI Pharma reports Q3 FY2024 cash $56.6M, no revenue; prioritizes voruciclib program

Lite Strategy, Inc.

2024-Q3 EPS reported $5.43 revenue$65,297,000

Cash, equivalents & investments $56.6M at Mar 31, 2024; no revenue for Q3 vs $5.9M prior year.
R&D expenses $5.2M (down from $15.1M YoY) due to zandelisib wind-down; G&A $4.6M (down from $7.2M).
Voruciclib Phase 1 expansion cohort enrolling; complete responses observed in R/R AML patients.
Board unanimously prioritizes voruciclib, decides against second return of capital under cooperation agreement.
ME-344 formulation development initiated; update expected in first half of calendar 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Lite Strategy, Inc. reported financial results for third quarter ended March 31, 2024.

Period: third quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 9, 2024, MEI Pharma, Inc. (the “Company”) issued a press release announcing its financial results for its third quarter ended March 31, 2024.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Lite Strategy, Inc. reported three and nine months ended March 31, 2024 results: net income As of March 31, 2024, MEI had $56.6 million in cash, cash equivalents, and short-term investments with no outstanding de.

Period: three and nine months ended March 31, 2024
Net income: As of March 31, 2024, MEI had $56.6 million in cash, cash equivalents, and short-term investments with no outstanding de
Result: reported results

Exact text from the filing

As of March 31, 2024, MEI had $56.6 million in cash, cash equivalents, and short-term investments with no outstanding debt.

View on SEC.gov

1053 earnings releases filed in the last 30 days. Browse all earnings releases →

Lite Strategy, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-056850

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.